Tredje AP fonden grew its stake in Iqvia Holdings Inc (NYSE:IQV) by 716.7% during the second quarter, HoldingsChannel reports. The firm owned 81,580 shares of the medical research company’s stock after purchasing an additional 71,591 shares during the period. Tredje AP fonden’s holdings in Iqvia were worth $8,143,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of IQV. IBM Retirement Fund purchased a new stake in Iqvia in the first quarter worth $345,000. BP PLC purchased a new stake in Iqvia in the second quarter worth $1,995,000. Jane Street Group LLC increased its position in Iqvia by 140.5% in the first quarter. Jane Street Group LLC now owns 35,075 shares of the medical research company’s stock worth $3,441,000 after buying an additional 20,492 shares during the last quarter. NN Investment Partners Holdings N.V. increased its position in Iqvia by 69.1% in the second quarter. NN Investment Partners Holdings N.V. now owns 22,857 shares of the medical research company’s stock worth $2,282,000 after buying an additional 9,344 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI purchased a new stake in Iqvia in the first quarter worth $306,000. Institutional investors own 94.93% of the company’s stock.

NYSE:IQV traded up $2.75 during trading hours on Tuesday, hitting $123.05. 4,790 shares of the company’s stock traded hands, compared to its average volume of 1,219,732. The firm has a market capitalization of $24.37 billion, a price-to-earnings ratio of 28.10, a P/E/G ratio of 1.73 and a beta of 0.72. Iqvia Holdings Inc has a 52 week low of $91.55 and a 52 week high of $125.35. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.13 and a current ratio of 1.13.

Iqvia (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 24th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.14 by $0.15. The company had revenue of $2.57 billion during the quarter, compared to analyst estimates of $2.50 billion. Iqvia had a return on equity of 13.51% and a net margin of 12.68%. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. equities analysts forecast that Iqvia Holdings Inc will post 5.13 earnings per share for the current fiscal year.

In related news, major shareholder Cpp Investment Board Private H sold 9,291,036 shares of Iqvia stock in a transaction on Friday, June 15th. The stock was sold at an average price of $103.00, for a total transaction of $956,976,708.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director John Connaughton sold 1,441,236 shares of Iqvia stock in a transaction on Friday, June 15th. The shares were sold at an average price of $103.00, for a total value of $148,447,308.00. The disclosure for this sale can be found here. Insiders have sold 11,201,623 shares of company stock valued at $1,160,990,595 in the last three months. 6.00% of the stock is owned by corporate insiders.

A number of analysts have issued reports on the company. ValuEngine downgraded Iqvia from a “buy” rating to a “hold” rating in a research report on Friday, June 22nd. Zacks Investment Research lowered Iqvia from a “buy” rating to a “hold” rating in a report on Monday. Royal Bank of Canada reaffirmed a “buy” rating and issued a $129.00 price target on shares of Iqvia in a report on Wednesday, July 25th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $97.00 price target on shares of Iqvia in a report on Wednesday, July 25th. Finally, Stifel Nicolaus raised their price target on Iqvia from $128.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday, July 25th. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. Iqvia presently has an average rating of “Buy” and a consensus target price of $124.44.

About Iqvia

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Read More: Asset Allocation and Your Retirement

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.